Frovatriptan

Chemical compound From Wikipedia, the free encyclopedia

Frovatriptan, sold under the brand name Frova among others, is a triptan medication developed by Vernalis for the treatment of migraine headaches[2] and for short term prevention of menstrual migraine.[3][4] The product is licensed to Endo Pharmaceuticals in North America and Menarini in Europe.[5]

Trade namesFrova
Other namesSB-209509; SB209509; EN-3266; EN3266; VML-251; VML251
AHFS/Drugs.comMonograph
MedlinePlusa604013
Quick facts Clinical data, Trade names ...
Frovatriptan
Clinical data
Trade namesFrova
Other namesSB-209509; SB209509; EN-3266; EN3266; VML-251; VML251
AHFS/Drugs.comMonograph
MedlinePlusa604013
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Oral
Drug classSerotonin 5-HT1B, 5-HT1D, 5-HT1F, and 5-HT7 receptor agonist
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability20–30%
MetabolismLiver
Elimination half-life26–30 hours[1]
ExcretionKidney
Identifiers
  • (+)-(R)-3-Methylamino-6-carboxamido-1,2,3,4-tetrahydrocarbazole
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H17N3O
Molar mass243.310 g·mol−1
3D model (JSmol)
  • CN[C@@H]3CCc2[nH]c1ccc(C(N)=O)cc1c2C3
  • InChI=1S/C14H17N3O/c1-16-9-3-5-13-11(7-9)10-6-8(14(15)18)2-4-12(10)17-13/h2,4,6,9,16-17H,3,5,7H2,1H3,(H2,15,18)/t9-/m1/s1 checkY
  • Key:XPSQPHWEGNHMSK-SECBINFHSA-N checkY
  (verify)
Close

Medical uses

Frovatriptan is used in the treatment of migraine.

Available forms

It is available as 2.5 mg tablets.

Contraindications

Frovatriptan should not be given to patients with:

  • Ischemic heart disease
  • Cerebrovascular syndrome
  • Peripheral vascular disease
  • Uncontrolled hypertension
  • Hemiplegic or basilar migraine

Side effects

Rare, but serious cardiac events have been reported in patients with risk factors predictive of CAD. These include: coronary artery vasospasm, transient myocardial ischemia, myocardial infarction, ventricular tachycardia and ventricular fibrillation.

Pharmacology

Pharmacodynamics

Further information: Serotonin receptor agonist and Triptan § Mechanism of action
More information Target, Affinity (Ki, nM) ...
Frovatriptan activities
TargetAffinity (Ki, nM)
5-HT1A50–62 (Ki)
759–>10,000 (EC50Tooltip half-maximal effective concentration)
38% (EmaxTooltip maximal efficacy)
5-HT1B2.5–46 (Ki)
6.3–20 (EC50)
92% (Emax)
5-HT1D1.7–10 (Ki)
2–5 (EC50)
98% (Emax)
5-HT1E>1,000 (Ki)
6,610–>10,000 (EC50)
44% (Emax)
5-HT1F63–120 (Ki)
79–447 (EC50)
46% (Emax)
5-HT2A>10,000 (Ki)
>10,000 (EC50)
5-HT2B>10,000 (Ki)
>10,000 (EC50)
5-HT2C>5,000 (Ki)
ND (EC50)
5-HT3>1,000 (mouse/rat)
5-HT4ND
5-HT5AND
5-HT6ND
5-HT7107–200 (Ki)
38 (EC50)
α1>10,000 (rat)
α1A–α1DND
α2A–α2CND
β1–β3ND
D1>10,000
D2>10,000
D3>10,000
D4–D5ND
H1>10,000 (guinea pig)
H2–H4ND
M1–M5ND
I1, I2ND
σ1, σ2ND
TAAR1Tooltip Trace amine-associated receptor 1ND
SERTTooltip Serotonin transporterND
NETTooltip Norepinephrine transporterND
DATTooltip Dopamine transporterND
Notes: The smaller the value, the more avidly the drug binds to the site. All proteins are human unless otherwise specified. Refs: [6][7][1][8][4][9][10]
[11][12][13][14][15]
Close

Frovatriptan is a serotonin receptor agonist, with high affinity for the serotonin 5-HT1B and 5-HT1D receptors and with weaker activity at the serotonin 5-HT1F receptor.[12] It has no significant effects on the GABAA mediated channel activity and benzodiazepine binding sites.[citation needed] Frovatriptan inhibits excessive dilation of arteries that supply blood to the head.[citation needed] Uniquely among most triptans, frovatriptan is also a relatively potent serotonin 5-HT7 receptor agonist.[12] It is inactive at the serotonin 5-HT2A and 5-HT2B receptors.[12]

Pharmacokinetics

Frovatriptan has a terminal elimination half-life of approximately 26 hours, making it the longest within its class.[16]

Chemistry

Frovatriptan's chemical structure is unusual among triptans, with other triptans being simple tryptamines or closely related compounds but frovatriptan instead being a tricyclic cyclized tryptamine and tetrahydrocarbazolamine derivative.[17] It can be thought of as a 5-substituted and side chain-cyclized derivative of N-methyltryptamine (NMT).[17]

The experimental log P of frovatriptan is 0.9 and its predicted log P is 1.2.[18]

History

Frovatriptan was first described in the scientific literature by 1997.[19][20][21] It was approved for medical use in the United States in 2001.[22]

Society and culture

Frovatriptan is available only by prescription in the United States and Canada.[23]

See also

References

Related Articles

Wikiwand AI